Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 plus cetrelimab versus concurrent chemoradiotherapy in muscle-invasive bladder cancer
2020-002620-36Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine-releasing intravesical system and cetrelimab in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Bladder-intact event-free survival. Started Dec 2020; status: active.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2020-002620-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002620-36.